Evidence map›Paper›PMID 35007320›Full record

ArticleDiabetes2022

Cytotoxicity-Related Gene Expression and Chromatin Accessibility Define a Subset of CD4+ T Cells That Mark Progression to Type 1 Diabetes.

Naiara G Bediaga, Alexandra L Garnham, Gaetano Naselli, Esther Bandala-Sanchez, Natalie L Stone, Joanna Cobb, Jessica E Harbison, John M Wentworth, Annette-G Ziegler, Jennifer J Couper and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. 1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit.International journal of molecular sciences · 2024
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Naiara G BediagaThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Alexandra L GarnhamThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Gaetano NaselliThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Esther Bandala-SanchezThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Natalie L StoneThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Joanna CobbMurdoch Children's Research Institute, Parkville, Australia.
Jessica E HarbisonDepartment of Endocrinology and Diabetes, Women's and Children's Hospital, North Adelaide, Australia.
John M WentworthThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-5197-3529
Annette-G ZieglerInstitute of Diabetes Research, Helmholtz Zentrum München, Neuherberg, Germany.ORCID 0000-0002-6290-5548
Jennifer J CouperDepartment of Endocrinology and Diabetes, Women's and Children's Hospital, North Adelaide, Australia.ORCID 0000-0003-4448-8629
Gordon K SmythThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Leonard C HarrisonThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-2500-8944
The University of Melbourne · AUWalter and Eliza Hall Institute of Medical Research · AUWomen's and Children's Hospital · AUHelmholtz Zentrum München · DEMurdoch Children's Research Institute · AUThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes in children is heralded by a preclinical phase defined by circulating autoantibodies to pancreatic islet antigens. How islet autoimmunity is initiated and then progresses to clinical diabetes remains poorly understood. Only one study has reported gene expression in specific immune cells of children at risk associated with progression to islet autoimmunity. We analyzed gene expression with RNA sequencing in CD4+ and CD8+ T cells, natural killer (NK) cells, and B cells, and chromatin accessibility by assay for transposase-accessible chromatin sequencing (ATAC-seq) in CD4+ T cells, in five genetically at risk children with islet autoantibodies who progressed to diabetes over a median of 3 years ("progressors") compared with five children matched for sex, age, and HLA-DR who had not progressed ("nonprogressors"). In progressors, differentially expressed genes (DEGs) were largely confined to CD4+ T cells and enriched for cytotoxicity-related genes/pathways. Several top-ranked DEGs were validated in a semi-independent cohort of 13 progressors and 11 nonprogressors. Flow cytometry confirmed that progression was associated with expansion of CD4+ cells with a cytotoxic phenotype. By ATAC-seq, progression was associated with reconfiguration of regulatory chromatin regions in CD4+ cells, some linked to differentially expressed cytotoxicity-related genes. Our findings suggest that cytotoxic CD4+ T cells play a role in promoting progression to type 1 diabetes.

Indexed as

Disease ProgressionGene Expression RegulationAdolescentAutoimmunityB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesChildChild, PreschoolChromatinCytotoxicity, ImmunologicDiabetes Mellitus, Type 1Genetic Predisposition to DiseaseHumansIslets of LangerhansKiller Cells, NaturalChromatin

Identifiers

PMID35007320
PMCPMC8893947
OpenAlexW4206389199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.